Akums Drugs & Pharmaceuticals will host its quarterly earnings conference call on August 10, 2026, to discuss its un-audited financial results for the first quarter of fiscal year 2027 (Q1FY27). The event provides investors and analysts with an opportunity to review the company’s performance for the period ending June 30, 2026, directly with senior management. This disclosure ensures transparency regarding the company’s operational and financial standing in the initial quarter of the new fiscal year.

The conference call is scheduled to begin at 12:00 PM IST and will be conducted virtually. Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company notified the National Stock Exchange of India Ltd and BSE Limited of the schedule. The management has clarified that no unpublished price-sensitive information (UPSI) will be shared during the meet. The schedule remains subject to change due to exigencies on the part of investors or the company.

Management Participation

The session will feature key executives from Akums Drugs and Pharmaceuticals Limited. The management team participating in the discussion includes:

• Sanjeev Jain, Managing Director
• Sandeep Jain, Managing Director
• Sumeet Sood, Chief Financial Officer
• Sahil Maheshwari, Head Strategy

The teleconference will be moderated by Umesh Laddha from Institutional Equities at Ambit Capital.

Dial-in Details

Investors and analysts can join the virtual meeting using the access numbers provided below. Participants are advised to dial in a few minutes prior to the scheduled start time to avoid delays. Registration via Diamond Pass is available to bypass wait times.

The disclosure was signed by Dharamvir Malik, Company Secretary & Compliance Officer, on August 05, 2026. A copy of this intimation has been updated on the company’s website at www.akums.in for public record.

Pure and Cure Healthcare Private Limited, a wholly-owned subsidiary of akums drugs & pharma , has acquired the manufacturing business of Oriflame India Private Limited for a total consideration of ₹56 crore. The Board of Directors approved the transaction on July 23, 2026, marking Akums' strategic entry into the color cosmetics segment while expanding its capabilities in skincare and wellness products for both Indian and global markets.

The acquisition includes two manufacturing facilities located in Roorkee, Uttarakhand, and Noida, Uttar Pradesh, along with a leased warehouse in Noida. Notably, the trademark and marketing rights for Oriflame’s products in India are excluded from this transaction. The move aims to leverage existing manufacturing capacity to diversify Akums' product portfolio beyond its core pharmaceutical operations.

Transaction Details

The deal is structured as a cash consideration purchase and is not classified as a related-party transaction. No promoter or group company holds an interest in the acquired business, ensuring the transaction was conducted at arm's length. The company confirmed that no prior governmental or regulatory approvals are required for this acquisition.

Strategic Implications

This acquisition represents a significant diversification step for Akums Drugs & Pharmaceuticals Limited. By acquiring established manufacturing infrastructure, the company can rapidly scale its presence in the fast-growing Indian cosmetics market without the lead time associated with greenfield projects. The inclusion of facilities in both Uttarakhand and Uttar Pradesh provides geographic diversification in production capabilities.

The exclusion of marketing and trademark rights suggests Akums intends to utilize these manufacturing assets for its own brands or contract manufacturing, rather than continuing the Oriflame brand portfolio. This approach allows the company to focus on operational efficiency and product development within the cosmetics and wellness space.

Regulatory Disclosures

The intimation was filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The disclosure was submitted to the National Stock Exchange of India Ltd and BSE Limited on July 23, 2026, at 5:56 PM IST. Dharamvir Malik, Company Secretary & Compliance Officer, signed the filing.